BioCryst Pharmaceuticals Inc (BCRX)
4.50
-0.08
(-1.75%)
USD |
NASDAQ |
Apr 18, 16:00
4.50
0.00 (0.00%)
After-Hours: 20:00
BioCryst Pharmaceuticals Free Cash Flow (Quarterly): -9.472M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -9.472M |
| September 30, 2023 | -20.88M |
| June 30, 2023 | -19.28M |
| March 31, 2023 | -47.67M |
| December 31, 2022 | -24.38M |
| September 30, 2022 | -32.62M |
| June 30, 2022 | -28.00M |
| March 31, 2022 | -78.21M |
| December 31, 2021 | -33.57M |
| September 30, 2021 | -23.64M |
| June 30, 2021 | -26.22M |
| March 31, 2021 | -61.11M |
| December 31, 2020 | -42.69M |
| September 30, 2020 | -38.43M |
| June 30, 2020 | -31.11M |
| March 31, 2020 | -23.40M |
| December 31, 2019 | -10.53M |
| September 30, 2019 | -27.72M |
| June 30, 2019 | -24.59M |
| March 31, 2019 | -27.09M |
| December 31, 2018 | -24.09M |
| September 30, 2018 | -35.07M |
| June 30, 2018 | -14.08M |
| March 31, 2018 | -19.69M |
| December 31, 2017 | -10.63M |
| Date | Value |
|---|---|
| September 30, 2017 | -12.62M |
| June 30, 2017 | -9.688M |
| March 31, 2017 | -8.53M |
| December 31, 2016 | -5.853M |
| September 30, 2016 | -17.74M |
| June 30, 2016 | -13.02M |
| March 31, 2016 | -22.10M |
| December 31, 2015 | -18.87M |
| September 30, 2015 | -12.80M |
| June 30, 2015 | 17.73M |
| March 31, 2015 | -4.291M |
| December 31, 2014 | -13.96M |
| September 30, 2014 | -8.634M |
| June 30, 2014 | -7.102M |
| March 31, 2014 | -8.966M |
| December 31, 2013 | -4.519M |
| September 30, 2013 | -7.922M |
| June 30, 2013 | -2.921M |
| March 31, 2013 | -11.20M |
| December 31, 2012 | -7.028M |
| September 30, 2012 | -11.78M |
| June 30, 2012 | -6.382M |
| March 31, 2012 | -12.32M |
| December 31, 2011 | -3.985M |
| September 30, 2011 | -10.47M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-78.21M
Minimum
Mar 2022
-9.472M
Maximum
Dec 2023
-31.76M
Average
-27.72M
Median
Sep 2019
Free Cash Flow (Quarterly) Benchmarks
| AIM ImmunoTech Inc | -9.956M |
| Perspective Therapeutics Inc | -9.097M |
| Protalix BioTherapeutics Inc | 3.345M |
| Electromed Inc | 3.384M |
| Armata Pharmaceuticals Inc | -10.51M |